接受15毫克剂量依度沙班的非瓣膜性心房颤动患者抗Xa因子活性分布情况
Distribution of anti-factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban.
作者信息
Hiramatsu Shotaro, Osanai Hiroyuki, Sakai Yuichiro, Sogo Yoshiki, Tanaka Yuki, Matsumoto Hikari, Miyamoto Shun, Tagahara Kensuke, Arai Kenji, Watanabe Takashi, Sakamoto Yusuke, Sakaguchi Teruhiro, Oguchi Shioh, Kanbara Takahiro, Nakashima Yoshihito, Asano Hiroshi, Ajioka Masayoshi
机构信息
Department of Cardiology Gifu Prefectural Tajimi Hospital Tajimi Gifu Japan.
Department of Cardiology Tosei General Hospital Seto Aichi Japan.
出版信息
J Arrhythm. 2024 Aug 27;40(5):1126-1130. doi: 10.1002/joa3.13139. eCollection 2024 Oct.
BACKGROUND
The distribution of anti-factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated.
METHODS AND RESULTS
The trough and peak AXA were measured in 19 NVAF patients taking edoxaban 15 mg. We compared these results with those in patients taking edoxaban 30 mg. The peak AXA differed significantly between the 15 mg and the 30 mg groups (0.74 ± 0.40 IU/mL vs. 1.25 ± 0.48 IU/mL, respectively; < 0.0001).
CONCLUSIONS
Peak but trough AXA in the patients receiving edoxaban 15 mg were significantly lower than those in patients receiving edoxaban 30 mg.
背景
服用15毫克依度沙班的非瓣膜性心房颤动（NVAF）患者中抗Xa因子活性（AXA）的分布尚未完全阐明。
方法与结果
对19例服用15毫克依度沙班的NVAF患者测量了AXA的谷值和峰值。我们将这些结果与服用30毫克依度沙班的患者的结果进行了比较。15毫克组和30毫克组的AXA峰值有显著差异（分别为0.74±0.40国际单位/毫升和1.25±0.48国际单位/毫升；<0.0001）。
结论
接受15毫克依度沙班治疗的患者的AXA峰值但谷值显著低于接受30毫克依度沙班治疗的患者。
Zotero 插件